Can I Take Melatonin with Wegovy? Interaction Risk, Timing, and Clinical Guidance

Wegovy contains semaglutide 2.4 mg, a GLP-1 receptor agonist that patients inject under the skin once per week; the FDA has approved it for chronic weight management in adults, while a lower-dose version sold as Ozempic is approved for type 2 diabetes. Melatonin, a hormone produced by the pineal gland, is available over the counter as a dietary supplement rather than as an FDA-approved medication, meaning the federal government does not regulate its dosage, purity, or label claims with the same standards applied to prescription drugs.

No published clinical trial has tested melatonin given together with semaglutide, and no pharmacokinetic interaction between the two is described in the current Wegovy prescribing information. The two compounds are cleared through unrelated pathways: semaglutide is broken down by proteolytic degradation, while melatonin is metabolized mainly by hepatic CYP1A2. That separation is the basis for saying most adults can take both without a drug-level conflict. The open question is not whether they interact pharmacokinetically (the evidence says they largely do not) but whether melatonin's known, dose-dependent effect on insulin secretion could work against one of the reasons a patient is taking semaglutide in the first place.

The direct answer

For most adults without diabetes or prediabetes, taking a standard low-dose melatonin supplement (roughly 0.5 to 3 mg) at bedtime alongside weekly Wegovy injections has no documented pharmacokinetic conflict and no reported pattern of serious harm in available data. The pharmacodynamic concern, that melatonin can blunt glucose-stimulated insulin release, is real at the level of melatonin's own pharmacology, but there is no direct evidence describing how that interacts with semaglutide's much larger glucose-lowering effect. Anyone with prediabetes, type 2 diabetes, or a family history of diabetes who wants to use melatonin above the lowest doses should discuss it with the prescriber managing their Wegovy treatment rather than assuming the two effects simply cancel out.

Why this question comes up

Sleep disruption is a common complaint during active weight loss, and Wegovy's prescribing information lists fatigue and insomnia among reported adverse events in its clinical trial program. Melatonin is one of the most widely used over-the-counter sleep aids in the United States; national health survey data collected by the CDC's National Health Interview Survey track supplement use trends including melatonin, though exact recent prevalence figures should be checked against the current NHIS release rather than assumed from older estimates (CDC NHIS). It is a predictable pattern: a patient starting Wegovy notices worse sleep and reaches for melatonin without necessarily checking with the prescriber first.

What is actually established versus assumed

Established: Semaglutide and melatonin are metabolized through different, non-overlapping pathways (proteolytic degradation versus CYP1A2), which is the pharmacological basis for saying they do not compete for clearance. The current FDA-approved Wegovy label does not list melatonin as a substance requiring dose adjustment or avoidance (FDA label, 2021). Melatonin receptors are expressed on pancreatic beta cells, and melatonin's role in modulating insulin secretion is a long-studied area of endocrine physiology.

Plausible but unproven in this combination: That melatonin's insulin-suppressing effect at higher doses could partially offset semaglutide's glucose-lowering benefit in some patients, particularly at night. This is a mechanistic inference built from separate lines of evidence (melatonin-glucose physiology and semaglutide's known glycemic profile), not from a study of the two together.

Not established: Any specific numeric estimate of how much melatonin blunts semaglutide's effect, any validated dose-separation window between the two, and any outcome data (weight loss, HbA1c, adherence) from patients using both concurrently. Claims stating precise percentages for this specific combination should be treated with skepticism until a dedicated study exists.

Semaglutide's clearance versus melatonin's metabolism

After weekly injections, semaglutide takes approximately one week to halve in concentration and reaches stable levels in the bloodstream after about a month of consistent dosing. The body eliminates semaglutide through protein breakdown rather than through liver enzyme metabolism. When taken by mouth, melatonin is rapidly eliminated from the body with a half-life usually shorter than an hour, reaches its highest blood levels within 20 to 60 minutes, and is broken down mainly by the CYP1A2 enzyme. Since semaglutide and melatonin use different metabolic pathways, neither is expected to meaningfully increase or decrease the blood concentration of the other.

Semaglutide slows gastric emptying, which is its main mechanism for reducing appetite and can theoretically delay absorption of anything taken with food. This matters little for melatonin taken at bedtime on a relatively empty stomach, since the delay would only meaningfully affect substances taken with a large meal.

Should you worry about glucose tolerance?

This is the part of the interaction question that has real biology behind it, even without a combination trial. Melatonin receptors, particularly MT2, are present on pancreatic beta cells, and activation of these receptors can inhibit glucose-stimulated insulin secretion. A genetic variant in the melatonin receptor gene (MTNR1B) that increases MT2 expression has been linked in observational research to modestly higher fasting glucose and impaired early insulin response, though the exact effect size varies across studies and should be verified against the primary literature rather than cited as a fixed number.

Separately, small trials in healthy volunteers have reported that a single higher dose of melatonin (around 5 mg) taken before bed can measurably reduce glucose tolerance the following morning, while other trials using low, prolonged-release doses (around 2 mg nightly) in people with type 2 diabetes already on metformin found no significant change in HbA1c or fasting glucose over several months. Taken together, this suggests the effect is dose-dependent: low doses appear to have a negligible metabolic footprint, while doses at or above 5 mg are more likely to produce a measurable, if modest, effect.

Semaglutide's own glucose-lowering effect, driven by glucose-dependent insulin secretion and slowed gastric emptying, is substantially larger than any glucose effect reported for standard-dose melatonin. That size difference is the practical reason most clinicians would not expect low-dose melatonin to meaningfully undercut semaglutide's benefit, but "substantially larger" is a reasoned inference from separate datasets, not a measured comparison from a trial that put both agents in the same patients.

Gastrointestinal overlap

Nausea is the most common adverse effect reported with Wegovy, especially during the dose-escalation phase, and is documented in the FDA-approved labeling (FDA label, 2021). Melatonin can also cause nausea, headache, or daytime grogginess, though at a lower rate in general population studies. If both effects occur together, the discomfort may feel additive even without a true pharmacological interaction. Starting melatonin at the lowest dose, apart from a large meal, and only after the initial Wegovy nausea has settled, is a reasonable way to isolate which agent is responsible for any new GI symptoms.

Timing: is dose separation necessary?

No regulator or guideline mandates a specific separation window between weekly semaglutide injections and nightly melatonin. Because Wegovy reaches steady plasma concentrations across the week, there is no pharmacological reason to avoid melatonin on any particular day relative to the injection. A practical approach some clinicians use is to have patients introduce a new supplement like melatonin starting a day or two after an injection, when acute post-injection GI symptoms tend to have settled, so that any new symptom can be attributed correctly. This is a matter of clinical judgment for symptom-tracking, not evidence of a required pharmacological delay.

Who should be more cautious

Patients with prediabetes or type 2 diabetes. Because melatonin's glucose effect is dose-dependent and mechanistically plausible, patients with existing dysglycemia who want melatonin above the lowest doses should discuss monitoring with the clinician managing their diabetes care, consistent with general guidance that any agent with glucose-modulating properties warrants closer glycemic monitoring in people with pre-existing dysglycemia.

Patients on CYP1A2 inhibitors. Drugs such as fluvoxamine and certain fluoroquinolone antibiotics inhibit CYP1A2 and can raise melatonin blood levels substantially, independent of any Wegovy interaction. Anyone on these medications should use the lowest melatonin dose available and tell their prescriber before starting it.

Older adults. Melatonin clearance slows with age, and professional sleep medicine guidance has generally advised caution about routine melatonin use for chronic insomnia in older adults, favoring behavioral approaches like cognitive behavioral therapy for insomnia as first-line treatment. This applies regardless of concurrent Wegovy use, but the sedation risk is worth flagging for older patients managing both a new GLP-1 medication and a sleep complaint.

Evidence-status interaction assessment

Monitoring in practice

Routine lab testing is not required for low-dose melatonin (0.5 to 3 mg) in an otherwise healthy adult on Wegovy. Checking fasting glucose or HbA1c is a reasonable precaution for patients with prediabetes, type 2 diabetes, or a strong family history of diabetes who use melatonin above 3 mg nightly for more than a few weeks. Watch for excessive daytime sleepiness, vivid dreaming, or morning grogginess, which suggest the melatonin dose is too high regardless of any Wegovy interaction. Contact a clinician if fasting glucose rises meaningfully above baseline without another explanation, if daytime sedation interferes with normal activities, or if GI symptoms become intolerable despite dose separation and titration.

What the research still needs to answer

No randomized trial has assigned patients on semaglutide to melatonin versus placebo and measured weight, glycemic, or sleep-quality outcomes. Everything in this article about the combination itself is inference from two separate evidence bases: melatonin's independent glucose physiology and semaglutide's independent clinical trial program. Whether improved sleep from melatonin use translates into better adherence to a GLP-1 regimen, and whether the MTNR1B genotype meaningfully changes risk in semaglutide users specifically, are open questions that have not been studied directly.

Bottom line

Melatonin and Wegovy can generally be used together without a known pharmacokinetic conflict. The realistic precaution is dose-dependent: keep melatonin at the lowest effective amount, take it apart from meals near bedtime, and add glucose monitoring only if you carry diabetes risk factors and want to use melatonin above roughly 3 mg. Anything more specific than that, a fixed percentage effect, a mandated separation window, or a guarantee of no interaction, outruns what the current evidence supports. This guidance is educational and does not replace individualized advice from the prescriber managing your Wegovy treatment. Seek urgent care for symptoms such as persistent vomiting, signs of severe hypoglycemia, or significant new confusion or sedation.